Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on March 30, 2010. The filing discloses the entry into a material definitive agreement involving an amendment to a prior collaboration.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a one-time payment obligation of $500,000 to be made by April 5, 2010.
Material Changes
On March 30, 2010, Omeros amended its July 25, 2008, Agreement for Antibody Discovery and Development with Affitech AS. Key changes include:
- Release of Obligations: Affitech released Omeros from all future royalty obligations (previously a low single-digit percentage on net sales of MASP-2 antibody products) and milestone payments (previously up to $10.1 million).
- Consideration: In exchange for the release, Omeros agreed to pay Affitech $500,000.
- Development Status: Both parties released each other from further development obligations under the agreement.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the amendment. The filing notes that the Original Agreement, as modified, remains in force. No specific guidance, future outlook, or new risk factors were disclosed in this report beyond the termination of the specific development and payment obligations with Affitech.
Investor Verification Checklist
- Verify the $500,000 payment status and timing (due April 5, 2010).
- Confirm the cessation of future royalty and milestone liabilities previously associated with the Affitech MASP-2 antibody program.
- Review the impact of terminating development obligations on Omeros's overall pipeline strategy.